NUS Links:
Gastric cancer (GC) has significant global mortality with high heterogeneity. A study of 226 GC samples from 121 patients integrated spatial transcriptomics and single-cell expression profiles, revealing extensive intratumour heterogeneity
The tumour microenvironment (TME) plays a pivotal role in cancer progression, metastasis, and therapeutic resistance. Comprised of diverse cells, extracellular matrix, and signaling molecules, the TME drives processes like epithelial-mesenchymal
Research led by N2CR member Dr. Cheok Chit Fang found that the tumour suppressor protein p53 protects DNA during replication by preventing the hyperactivation of PARP1 caused by oxidative stress.
CIITA is the master regulator of MHC class-II immune genes that are important for defense mechanism against infections and cancer development. CIITA is controlled by three specific switches used in
Chemotherapy, although the first line of defense in cancer treatment, is indiscriminate and is damaging to the entire body, which, ironically, worsens a patient’s chances of getting better from cancer.
This research, led by N2CR members Prof Goh Boon Cher and Prof Shazib Pervaiz with Dr Jayshree Hirpara as the first author, investigates the role of extracellular vesicles (EVs) in
Detecting cancer-driving mutations is crucial for understanding cancer and developing treatments. Existing prediction tools vary in accuracy. N2CR member A/Prof Chen Ee Sin co-led the study on DriverDetect, a machine
Led by N2CR member A/Prof Polly Chen, this research highlights the crucial role of ‘death associated protein 3’ (DAP3) in regulating N6-methyladenosine (m6A) RNA methylation, a process often disrupted in
Relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) is challenging to treat. Outcome for such patients is dismal. A recent experimental treatment – using CD7 CAR T-cell therapy, developed by N2CR member
A recent phase l trial evaluated the safety and efficacy of combining pressurised intraperitoneal aerosol chemotherapy-oxaliplatin (PIPAC-OX) with nivolumab in patients with gastric cancer peritoneal metastases (GCPM). Eighteen patients from